Cargando…
Definitive study shows no association between ARID1A mutation status and clinical outcome in endometriosis‐related ovarian cancers
The ARID1A tumour suppressor protein is a component of the SWI/SNF chromatin remodelling complex, which is mutated in approximately 20% of all human cancers. ARID1A mutational status is considered to hold prognostic significance in a range of solid malignancies, yet in endometriosis‐related ovarian...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540905/ https://www.ncbi.nlm.nih.gov/pubmed/35647895 http://dx.doi.org/10.1002/path.5973 |
_version_ | 1784803806946525184 |
---|---|
author | Khalique, Saira Nash, Sarah Natrajan, Rachael |
author_facet | Khalique, Saira Nash, Sarah Natrajan, Rachael |
author_sort | Khalique, Saira |
collection | PubMed |
description | The ARID1A tumour suppressor protein is a component of the SWI/SNF chromatin remodelling complex, which is mutated in approximately 20% of all human cancers. ARID1A mutational status is considered to hold prognostic significance in a range of solid malignancies, yet in endometriosis‐related ovarian carcinomas there has been a lack of clarity of its prognostic role. Moreover, the relationship between ARID1A status and immune infiltrate is also poorly understood. In a recent issue of The Journal of Pathology, a large comprehensive study by Heinze, Nazeran et al addressed these areas by reviewing 1,623 endometriosis‐associated ovarian carcinomas and correlating ARID1A status using standardised immunohistochemistry to infer mutation status, with comprehensive clinicopathological features, mismatch repair status and CD8(+) tumour infiltrating lymphocytes. The study definitively showed that ARID1A status does not provide any independent prognostic value in endometriosis‐associated ovarian carcinomas. ARID1A loss was, however, shown to be associated with mismatch repair deficiency and increased CD8(+) tumour infiltrating lymphocytes in endometrioid ovarian carcinoma, which may be relevant for future studies. © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland. |
format | Online Article Text |
id | pubmed-9540905 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley & Sons, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-95409052022-10-14 Definitive study shows no association between ARID1A mutation status and clinical outcome in endometriosis‐related ovarian cancers Khalique, Saira Nash, Sarah Natrajan, Rachael J Pathol Invited Commentary The ARID1A tumour suppressor protein is a component of the SWI/SNF chromatin remodelling complex, which is mutated in approximately 20% of all human cancers. ARID1A mutational status is considered to hold prognostic significance in a range of solid malignancies, yet in endometriosis‐related ovarian carcinomas there has been a lack of clarity of its prognostic role. Moreover, the relationship between ARID1A status and immune infiltrate is also poorly understood. In a recent issue of The Journal of Pathology, a large comprehensive study by Heinze, Nazeran et al addressed these areas by reviewing 1,623 endometriosis‐associated ovarian carcinomas and correlating ARID1A status using standardised immunohistochemistry to infer mutation status, with comprehensive clinicopathological features, mismatch repair status and CD8(+) tumour infiltrating lymphocytes. The study definitively showed that ARID1A status does not provide any independent prognostic value in endometriosis‐associated ovarian carcinomas. ARID1A loss was, however, shown to be associated with mismatch repair deficiency and increased CD8(+) tumour infiltrating lymphocytes in endometrioid ovarian carcinoma, which may be relevant for future studies. © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland. John Wiley & Sons, Ltd 2022-06-29 2022-09 /pmc/articles/PMC9540905/ /pubmed/35647895 http://dx.doi.org/10.1002/path.5973 Text en © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Invited Commentary Khalique, Saira Nash, Sarah Natrajan, Rachael Definitive study shows no association between ARID1A mutation status and clinical outcome in endometriosis‐related ovarian cancers |
title | Definitive study shows no association between
ARID1A
mutation status and clinical outcome in endometriosis‐related ovarian cancers
|
title_full | Definitive study shows no association between
ARID1A
mutation status and clinical outcome in endometriosis‐related ovarian cancers
|
title_fullStr | Definitive study shows no association between
ARID1A
mutation status and clinical outcome in endometriosis‐related ovarian cancers
|
title_full_unstemmed | Definitive study shows no association between
ARID1A
mutation status and clinical outcome in endometriosis‐related ovarian cancers
|
title_short | Definitive study shows no association between
ARID1A
mutation status and clinical outcome in endometriosis‐related ovarian cancers
|
title_sort | definitive study shows no association between
arid1a
mutation status and clinical outcome in endometriosis‐related ovarian cancers |
topic | Invited Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540905/ https://www.ncbi.nlm.nih.gov/pubmed/35647895 http://dx.doi.org/10.1002/path.5973 |
work_keys_str_mv | AT khaliquesaira definitivestudyshowsnoassociationbetweenarid1amutationstatusandclinicaloutcomeinendometriosisrelatedovariancancers AT nashsarah definitivestudyshowsnoassociationbetweenarid1amutationstatusandclinicaloutcomeinendometriosisrelatedovariancancers AT natrajanrachael definitivestudyshowsnoassociationbetweenarid1amutationstatusandclinicaloutcomeinendometriosisrelatedovariancancers |